Pfizer Ltd. (PFIZER) 52 Week Low Streak Extends to Fourth Session

Pfizer Ltd. (PFIZER) has now traded within 2% of its 52-week low for its fourth consecutive session, with a cumulative decline of 4.84% across the streak. During the current move, the stock touched a low of Rs 3,684.55 and was last trading at Rs 3,735. The latest Univest data confirms the repeated-low pattern, but it does not establish any company-specific cause for the continued weakness.

At 10:52 AM IST, the previous close stood at Rs 3,762.3, while the stock opened at Rs 3,764.95 and touched a high of Rs 3,765. The market capitalisation stood at Rs 17,417.08 crore, placing the current decline in the context of a large listed pharma business that is still being priced close to its yearly low. For readers, the repeated pattern matters more than a single session because it shows persistent pressure across several trading days rather than one isolated move.

Pfizer Ltd. 52 Week Low Streak: Consecutive Low Analysis

Metric	Value
Current Price	Rs 3,735
Previous Close	Rs 3,762.3
Today's Move	Rs -27.3 (-0.73%)
Open	Rs 3,764.95
High	Rs 3,765
Low	Rs 3,684.55
Market Capitalisation	Rs 17,417.08 crore

Pfizer Ltd. (PFIZER) traded at Rs 3,735 versus the previous close of Rs 3,762.3, a fall of 0.73%. The stock opened at Rs 3,764.95, reached a high of Rs 3,765, touched a low of Rs 3,684.55.

Pfizer Ltd. share price today is lower by Rs 27.3, or 0.73%, versus the previous close of Rs 3,762.3, with the stock last trading at Rs 3,735. The day opened almost flat at Rs 3,764.95 and then moved down to an intraday low of Rs 3,684.55 before recovering part of the drop. The highest point seen so far is Rs 3765, which shows that the price has stayed near the upper end only briefly before slipping back toward the lower band of the day.

That intraday structure keeps the Pfizer Ltd. share price in focus because the move remains aligned with the broader 52-week low streak rather than a one-off dip. The market capitalisation of Rs 17,417.08 crore indicates a substantial listed company, so the present weakness is being watched through both the stock price and the company’s valuation profile. For anyone tracking Pfizer Ltd. stock news, the key point is not just the day’s decline, but the fact that the stock is still hovering close to its one-year trough for a fourth straight session. This is a decline story, and the price action continues to reflect that pattern.

What the Repeated 52-Week Lows Show

The extended streak shows that Pfizer Ltd. has not merely tested its yearly low once; it has kept trading within 2% of that level across four consecutive sessions. Across the full stretch, the cumulative move is down 4.84%, which gives a clearer read than the day’s change alone. That wider move is the main differentiator in a Pfizer Ltd. 52 Week Low Streak article, because it highlights a sustained pattern of weakness rather than a single-day event.

For market readers, the repeated placement near the one-year low means the stock remains under pressure across successive sessions. The latest Univest data confirms that pattern, but it does not confirm a company-specific trigger for why the stock has remained near this range. In other words, the numbers show persistence, not a verified reason. That distinction matters because a repeated low can continue for several sessions without a fresh headline, and the data here supports that reading. The move also keeps the Pfizer Ltd. share price under close watch in the context of broader stock performance.

Pfizer Ltd. (PFIZER) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 17,417.08 crore
P/E Ratio	23.41x
P/B Ratio	3.91x
ROE	17.16%
ROCE	23.39%
EPS	Rs 160.7
Book Value Per Share	Rs 963.41
Dividend Yield	1.99%

Pfizer Ltd. (PFIZER) fundamental metrics show P/E 23.41x, P/B 3.91x, ROE 17.16%, ROCE 23.39%. These figures provide context only and are not a buy or sell signal.

Pfizer Ltd. has a market capitalisation of Rs 17,417.08 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 23.41x, P/B at 3.91x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 17.16% and ROCE of 23.39%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 160.7, book value per share of Rs 963.41, dividend yield of 1.99%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 27.02x, median ROE of 11.23%, median ROCE of 13.17%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	23.41x
Benchmark Median P/E	27.02x
Benchmark Average P/E	38.85x
Benchmark P/E Range	0x to 616.23x
Company P/B Ratio	3.91x
Benchmark Median P/B	2.67x
Company ROE	17.16%
Benchmark Median ROE	11.23%
Company ROCE	23.39%
Benchmark Median ROCE	13.17%
Company Market Capitalisation	Rs 17,417.08 crore
Benchmark Median Market Cap	Rs 768.75 crore

Pfizer Ltd. (PFIZER) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Pfizer Ltd. (PFIZER) has a P/E ratio of 23.41x, which is below the benchmark median of 27.02x, a difference of -13.36%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Pfizer Ltd. (PFIZER) has a ROE of 17.16%, which is above the benchmark median of 11.23%, a difference of +52.8%. Pfizer Ltd. (PFIZER) has a ROCE of 23.39%, which is above the benchmark median of 13.17%, a difference of +77.6%.

Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Suven Pharmaceuticals Ltd.	COHANCE	17,513.39	165.48	4.57	4.02	6.12
Caplin Point Laboratories Ltd.	CAPLIPOINT	17,194.23	25.38	4.6	20.79	24.97
Shilpa Medicare Ltd.	SHILPAMED	17,131.99	55.58	6.15	9.82	11.43
ONESOURCE SPECL PHARMA L	ONESOURCE	15,818.68	0	2.65	-1.26	0.44
Natco Pharma Ltd.	NATCOPHARM	15,708.15	13.46	1.65	16.3	17.16

Pfizer Ltd. (PFIZER) has a P/E ratio of 23.41x compared with the displayed peer median of 25.38x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 17.16% compares with a peer median of 9.82% across the companies shown in the table. ROCE stood at 23.39% versus the displayed peer median of 11.43%, providing a capital-efficiency comparison. Pfizer Ltd. (PFIZER) has a market capitalisation of Rs 17,417.08 crore. Among the 5 peers shown, only 1 has a larger market capitalisation.

Why Investors Are Watching

• The stock has traded within 2% of its 52-week low for a fourth consecutive session, which makes the Pfizer Ltd. 52 Week Low Streak more than a one-day event.
• The cumulative decline across the streak is 4.84%, giving a better read on the full weakness than the latest move alone.
• The latest Univest data confirms the repeated-low pattern, but it does not establish a company-specific cause for the continued move.
• Pfizer Ltd. is still valued above the industry median on P/B while trading below the industry median on P/E, so the valuation picture is mixed.
• The stock’s profitability ratios remain above the industry median, so investors will likely keep watching whether price weakness persists despite solid return metrics.

About the Company

Pfizer Ltd. is part of the Healthcare sector and the Pharmaceuticals & Drugs industry in India. The company’s market capitalisation stands at Rs 17,417.08 crore, and its latest profitability metrics show ROE of 17.16% and ROCE of 23.39%. The stock is tracked on both NSE and BSE, and its current share price action remains central to Pfizer Ltd. stock performance discussions.

For readers following Pfizer Ltd. share price update alongside company financials, the main point is that the stock remains a sizeable listed pharma name with mixed valuation signals. The current near 52-week low pattern does not by itself explain the business outlook, but it does make the company’s earnings quality, book value and sector comparison more relevant for ongoing monitoring.

Frequently Asked Questions

Why is Pfizer Ltd. still near its 52-week low?

Ans. Pfizer Ltd. has traded within 2% of its 52-week low for four consecutive sessions. The data confirms the pattern, but it does not establish a company-specific cause for the continued weakness.

How does Pfizer Ltd. compare with peers on valuation?

Ans. Pfizer Ltd. trades at a P/E of 23.41 and a P/B of 3.91. That places it below the industry median on earnings multiple but above the median on book value multiple.

Is Pfizer Ltd. expensive compared with the sector?

Ans. The answer is mixed. Its P/E is below the industry median, but its P/B is above the median. Investors should view the valuation in the context of profitability and peer comparison.

What fundamental metrics stand out for Pfizer Ltd.?

Ans. ROE of 17.16% and ROCE of 23.39% stand out positively versus the industry median. EPS of Rs 160.7 and book value of Rs 963.41 are also important markers in the current Pfizer Ltd. stock analysis.

What should investors monitor next in Pfizer Ltd. stock news?

Ans. Investors should watch whether the stock continues to trade near its yearly low, how the share price behaves relative to the latest range, and whether future updates change the valuation or fundamental picture.

Track Pfizer Ltd. (PFIZER) Share Price on Univest

Use Pfizer Ltd. (PFIZER) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.